Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

2019; Springer Science+Business Media; Volume: 21; Issue: 1 Linguagem: Inglês

10.1007/s10198-019-01117-3

ISSN

1618-7601

Autores

Marscha S. Holleman, Maiwenn Al, Remziye Zaim, Harry J.M. Groen, Carin A. Uyl‐de Groot,

Tópico(s)

Colorectal Cancer Treatments and Studies

Resumo

To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations.

Referência(s)